Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 박종호 | - |
dc.date.accessioned | 2021-04-16T00:34:24Z | - |
dc.date.available | 2021-04-16T00:34:24Z | - |
dc.date.issued | 2020-02 | - |
dc.identifier.citation | ANNALS OF NEUROLOGY, v. 87, no. 2, page. 233-245 | en_US |
dc.identifier.issn | 0364-5134 | - |
dc.identifier.issn | 1531-8249 | - |
dc.identifier.uri | https://onlinelibrary.wiley.com/doi/full/10.1002/ana.25644 | - |
dc.identifier.uri | https://repository.hanyang.ac.kr/handle/20.500.11754/161511 | - |
dc.description.abstract | Objective: Otaplimastat is a neuroprotectant that inhibits matrix metalloprotease pathway, and reduces edema and intracerebral hemorrhage induced by recombinant tissue plasminogen activator (rtPA) in animal stroke models. We aimed to assess the safety and efficacy of otaplimastat in patients receiving rtPA. Methods: This was a phase 2, 2-part, multicenter trial in stroke patients (19-80 years old) receiving rtPA. Intravenous otaplimastat was administered <30 minutes after rtPA. Stage 1 was a single-arm, open-label safety study in 11 patients. Otaplimastat 80 mg was administered twice daily for 3 days. Stage 2 was a randomized, double-blind, placebo-controlled study involving 69 patients, assigned (1:1:1) to otaplimastat 40 mg, otaplimastat 80 mg, or a placebo. The primary endpoint was the occurrence of parenchymal hematoma (PH) on day 1. Secondary endpoints included serious adverse events (SAEs), mortality, and modified Rankin scale (mRS) distribution at 90 days ( identifier: NCT02787278). Results: No safety issues were encountered in stage 1. The incidence of PH during stage 2 was comparable: 0 of 22 with the placebo, 0 of 22 with otaplimastat 40 mg, and 1 of 21 with the 80 mg dose. No differences in SAEs (13%, 17%, 14%) or death (8.3%, 4.2%, 4.8%) were observed among the 3 groups. Three adverse events (chills, muscle rigidity, hepatotoxicity) were judged to be related to otaplimastat. Interpretation: Intravenous otaplimastat adjunctive therapy in patients receiving rtPA is feasible and generally safe. The functional efficacy of otaplimastat needs to be investigated with further large trials. | en_US |
dc.description.sponsorship | This study was supported by a grant from the Korea Health Technology R&D project through the Korea Health Industry Development Institute, funded by the Ministry of Health & Welfare, Republic of Korea (HI15C2796). | en_US |
dc.language.iso | en | en_US |
dc.publisher | WILEY | en_US |
dc.subject | TISSUE-PLASMINOGEN ACTIVATOR | en_US |
dc.subject | HEMORRHAGIC TRANSFORMATION | en_US |
dc.subject | MATRIX METALLOPROTEINASES | en_US |
dc.subject | THROMBOLYTIC THERAPY | en_US |
dc.subject | ALTEPLASE | en_US |
dc.subject | THROMBECTOMY | en_US |
dc.subject | INJURY | en_US |
dc.subject | BRAIN | en_US |
dc.title | Safety and Efficacy of Otaplimastat in Patients with Acute Ischemic Stroke Requiring tPA (SAFE-TPA): A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study | en_US |
dc.type | Article | en_US |
dc.identifier.doi | 10.1002/ana.25644 | - |
dc.relation.page | 233-245 | - |
dc.relation.journal | ANNALS OF NEUROLOGY | - |
dc.contributor.googleauthor | Kim, Jong S. | - |
dc.contributor.googleauthor | Lee, Kyung Bok | - |
dc.contributor.googleauthor | Park, Jong-Ho | - |
dc.contributor.googleauthor | Sung, Sang Min | - |
dc.contributor.googleauthor | Oh, Kyungmi | - |
dc.contributor.googleauthor | Kim, Eung-Gyu | - |
dc.contributor.googleauthor | Chang, Dae-il | - |
dc.contributor.googleauthor | Hwang, Yang Ha | - |
dc.contributor.googleauthor | Lee, Eun-Jae | - |
dc.contributor.googleauthor | Kim, Won-Ki | - |
dc.relation.code | 2020045895 | - |
dc.sector.campus | S | - |
dc.sector.daehak | COLLEGE OF MEDICINE[S] | - |
dc.sector.department | DEPARTMENT OF MEDICINE | - |
dc.identifier.pid | jhpark619 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.